Correale P, Pentimalli F, Baglio G, Krstic-Demonacos M, Saladino RE, Giordano A, et al. Is there already a need of reckoning on cancer immunotherapy? Front Pharmacol. 2021;12:638279.
Article
Google Scholar
Chow RD, Bradley EH, Gross CP. Comparison of cancer-related spending and mortality rates in the US vs 21 high-income countries. JAMA Health Forum. 2022;3(5):e221229.
Article
Google Scholar
Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw Open. 2022;5(8):e2225973.
Article
Google Scholar
XPO1 Inhibitor Approved for Multiple Myeloma. Cancer Discov. 2019;9(9):1150-1151. https://doi.org/10.1158/2159-8290.CD-NB2019-085. Epub 2019 Jul 22. PMID: 31332020.
DasGupta R, Yap A, Yaqing EY, Chia S. Evolution of precision oncology-guided treatment paradigms. WIREs
Mech Dis. 2022;27:e1585. https://doi.org/10.1002/wsbm.1585 (Epub ahead of print. PMID: 36168283).
Article
Google Scholar
Olivier T, Haslam A, Prasad V. Anticancer drugs approved by the US food and drug administration from 2009 to 2020 according to their mechanism of action. JAMA Netw Open. 2021;4(12):e2138793.
Article
Google Scholar
Vincent Rajkumar S. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6):71.
Article
CAS
Google Scholar
Stacchiotti S, Schoffski P, Jones R, Agulnik M, Villalobos VM, Jahan TM, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). J Clin Oncol. 2019;37(15_suppl):11003-.
Article
Google Scholar
Hoy SM. Tazemetostat. First Approval Drugs. 2020;80(5):513–21.
Google Scholar
Avapritinib Approved for GIST Subgroup. Cancer Discov. 2020;10(3):334. https://doi.org/10.1158/2159-8290.CDNB2020-002 (Epub 2020 Jan 23. PMID: 31974168).
Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600.
Article
CAS
Google Scholar
Li G, Liu X, Chen X. Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 2020;17(10):589–90.
Article
Google Scholar
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.
Article
CAS
Google Scholar
Marcus L, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, et al. FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res. 2021;27(4):928–32.
Article
CAS
Google Scholar
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261–70.
Article
CAS
Google Scholar
Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Rev Anticancer Ther. 2020;20(5):333–41.
Article
CAS
Google Scholar
Shen C, Ferro EG, Xu H, Kramer DB, Patell R, Kazi DS. Underperformance of contemporary phase III oncology trials and strategies for improvement. J Natl Compr Canc Netw. 2021;19(9):1072–8.
Article
Google Scholar
Hahn AW, Dizman N, Msaouel P. Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. Ther Adv Med Oncol. 2022;14:17588359221103200.
Article
Google Scholar
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446–51.
Article
CAS
Google Scholar
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86.
Article
CAS
Google Scholar
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488–99.
Article
CAS
Google Scholar
Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004;9(5):482–8.
Article
CAS
Google Scholar
Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, et al. A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern. JTO Clin Res Rep. 2022;3(3):100280.
Google Scholar
Messori A, Trippoli S. Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials. J Chemother. 2022;12:1–5. https://doi.org/10.1080/1120009X.2022.2061183 (Epub ahead of print. PMID: 35411826).
Article
Google Scholar
Tagliamento M, Bironzo P, Curcio H, De Luca E, Pignataro D, Rapetti SG, et al. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. Crit Rev Oncol Hematol. 2022;172:103639.
Article
Google Scholar
Pass HI. Commentary: A chess game for mesothelioma treatment: Not checkmate yet! J Thorac Cardiovasc Surg. 2022;S0022-5223(22)00127-1. https://doi.org/10.1016/j.jtcvs.2022.02.003 (Epub ahead of print. PMID: 35227497).
Bomze D, Asher N, Hasan Ali O, Flatz L, Azoulay D, Markel G, et al. Survival-inferred fragility index of phase 3 clinical trials evaluating immune checkpoint inhibitors. JAMA Netw Open. 2020;3(10):e2017675.
Article
Google Scholar
Bomze D, Azoulay D, Meirson T. Immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer. JAMA Oncol. 2020;6(7):1114–5.
Article
Google Scholar
Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, et al. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio. JAMA Oncol. 2017;3(12):1692–6.
Article
Google Scholar
Gilboa S, Pras Y, Mataraso A, Bomze D, Markel G, Meirson T. Informative censoring of surrogate end-point data in phase 3 oncology trials. Eur J Cancer. 2021;153:190–202.
Article
Google Scholar
Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, et al. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open. 2022;5(3):e221490.
Article
Google Scholar
Templeton AJ, Amir E, Tannock IF. Informative censoring—a neglected cause of bias in oncology trials. Nat Rev Clin Oncol. 2020;17(6):327–8.
Article
Google Scholar
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14.
Article
CAS
Google Scholar
Nord CL, Valton V, Wood J, Roiser JP. Power-up: a reanalysis of ‘power failure’ in neuroscience using mixture modeling. J Neurosci. 2017;37(34):8051–61.
Article
CAS
Google Scholar
Correale P, Pentimalli F, Nardone V, Giordano A, Mutti L. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? Lancet Oncol. 2022;23(1):e13.
Article
Google Scholar
Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med. 2021;9(9):969–76.
Article
Google Scholar
Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27(11):1910–20.
Article
CAS
Google Scholar
Fujimoto N, Okada M, Kijima T, Aoe K, Kato T, Nakagawa K, et al. Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study. JTO Clin Res Rep. 2021;2(3):100135.
Google Scholar
Barbarino M, Bottaro M, Luzzi L, Giordano A, Mutti L. Tumour treating fields for mesothelioma. Lancet Oncol. 2020;21(1):e8.
Article
Google Scholar
Porta C, Nardone V, Gray SG, Correale P, Mutti L. RAMES study: is there really a role for VEGF inhibition in mesothelioma? Lancet Oncol. 2021;22(12):e532.
Article
CAS
Google Scholar
Nardone V, Porta C, Giannicola R, Correale P, Mutti L. Abemaciclib for malignant pleural mesothelioma. Lancet Oncol. 2022;23(6):e237.
Article
CAS
Google Scholar
Zabor EC, Kane MJ, Roychoudhury S, Nie L, Hobbs BP. Bayesian basket trial design with false-discovery rate control. Clin Trials. 2022;19(3):297–306.
Article
Google Scholar
Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, et al. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 2020;10(8):1103–20.
Article
CAS
Google Scholar
LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21(11):1344–9.
Article
CAS
Google Scholar
Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022;23(6):758–67.
Article
CAS
Google Scholar
Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer. 2019;19(1):108.
Article
Google Scholar
Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, et al. A Novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair. J Thorac Oncol. 2017;12(8):1309–19.
Article
Google Scholar
Ghafoor A, Mian I, Wagner C, Mallory Y, Agra MG, Morrow B, et al. Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene. JTO Clin Res Rep. 2021;2(10):100231.
Google Scholar
Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593–600.
Article
CAS
Google Scholar
Dudnik E, Bar J, Moore A, Gottfried T, Moskovitz M, Dudnik J, et al. BAP1-altered malignant pleural mesothelioma: outcomes with chemotherapy, immune check-point inhibitors and poly(ADP-Ribose) polymerase inhibitors. Front Oncol. 2021;11:603223.
Article
Google Scholar
Pinton G, Manente AG, Murer B, De Marino E, Mutti L, Moro L. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. J Cell Mol Med. 2013;17(2):233–41.
Article
Google Scholar
Gabano E, Pinton G, Balzano C, Boumya S, Osella D, Moro L, et al. Unsymmetric cisplatin-based Pt(IV) conjugates containing a PARP-1 inhibitor pharmacophore tested on malignant pleural mesothelioma cell lines. Molecules. 2021;26(16):4740.
Article
CAS
Google Scholar
Busacca S, Sheaff M, Arthur K, Gray SG, O’Byrne KJ, Richard DJ, et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol. 2012;227(2):200–8.
Article
CAS
Google Scholar
He Q, Zhang M, Zhang J, Zhong S, Liu Y, Shen J, et al. Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents. Ann Transl Med. 2016;4(6):110.
Article
Google Scholar
Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, et al. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial. EClinicalMedicine. 2022;48:101432.
Article
Google Scholar
Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2012;70(5):743–54.
Article
CAS
Google Scholar
Busacca S, O’Regan L, Singh A, Sharkey AJ, Dawson AG, Dzialo J, et al. BRCA1/MAD2L1 deficiency disrupts the spindle assembly checkpoint to confer vinorelbine resistance in mesothelioma. Mol Cancer Ther. 2021;20(2):379–88.
Article
CAS
Google Scholar
Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, et al. Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma. Lung Cancer. 2019;127:164–6.
Article
Google Scholar
Passiglia F, Bironzo P, Righi L, Listì A, Arizio F, Novello S, et al. A prospective phase II single-arm study of niraparib plus dostarlimab in patients with advanced non-small-cell lung cancer and/or malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: rationale and study design. Clin Lung Cancer. 2021;22(1):e63–6.
Article
Google Scholar
Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, et al. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Sci Rep. 2021;11(1):21357.
Article
CAS
Google Scholar
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.
Article
Google Scholar
Pirtoli L, Alia L, Zacchini S. Oncology and a time of crisis. Science, complexity, ethic values, and incertitude. An argumentative essay. Medicus. 2021;5:104–17.
Google Scholar
Yang L, Cao X, Li N, Zheng B, Liu M, Cai H. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol. 2022;14:17588359221116604.
Article
Google Scholar
Ye ZM, Tang ZQ, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10:947375.
Article
Google Scholar
Michaeli DT, Michaeli T. Overall Survival, Progression-free survival, and tumor response benefit supporting initial US food and drug administration approval and indication extension of new cancer drugs, 2003-2021. J Clin Oncol. 2022;JCO2200535. https://doi.org/10.1200/JCO.22.00535 (Epub ahead of print. PMID: 35921606)
Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018;19(1):233.
Article
Google Scholar
Borrelli EP, McGladrigan CG. A review of pharmacologic management in the treatment of mesothelioma. Curr Treat Options Oncol. 2021;22(2):14.
Article
Google Scholar
Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice. Value Health. 2008;11(1):4–12.
Article
Google Scholar
Zhan M, Zheng H, Xu T, Yang Y, Li Q. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung Cancer. 2017;110:1–6.
Article
Google Scholar
Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, et al. BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study. J Thorac Oncol. 2022;17(7):921–30.
Article
CAS
Google Scholar
Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, et al. BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci. 2019;20(2):429.
Article
Google Scholar
Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, et al. Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma. Clin Cancer Res. 2021;27(8):2277–91.
Article
CAS
Google Scholar
Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):374–81.
Article
CAS
Google Scholar
Strzebonska K, Waligora M. Umbrella and basket trials in oncology: ethical challenges. BMC Med Ethics. 2019;20(1):58.
Article
Google Scholar
Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev. 2019;73:20–30.
Article
Google Scholar
Kindler HL. Systemic therapy for mesothelioma: turning the corner. JCO Oncol Pract. 2022;18(6):e843–5.
Google Scholar
Nowak AK, Jackson A, Sidhu C. Management of advanced pleural mesothelioma-at the crossroads. JCO Oncol Pract. 2022;18(2):116–24.
Article
Google Scholar
Fennell DA, Dulloo S, Harber J. Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol. 2022;19(9):573–84.
Article
CAS
Google Scholar
Ratain MJ. Oncology drug prescribing: the influences of greed and fear. JCO Oncol Pract. 2022;18(9):e1384–7.
Google Scholar